P2579Differential microRNA gene expression levels in patients with acute myocarditis

Abstract

Background:The objective of this study was to identify prognostic indicators in patients with inflammatoric cardiomyopathy (CMi) on endomyocardial biopsy (EMB). Methods: Between 2007 and 2012 all consecutive patients with CMi on EMB were retrospectively analyzed. The combined primary endpoint was cardiac death, survived sudden cardiac death, appropriate ICD shock, heart transplantation, and LVAD implantation. Results: 503 consecutive patients (mean age 58±12 years, 73% male) were available for analysis. During mean 3.6±2.4 years of follow-up (FU), 40 patients (8.6%) reached the primary endpoint, which was in 14 patients cardiac death (cardiac mortality 3.0%). Independent predictors for the primary endpoint were age ≥50 years, symptoms of congestive heart failure, and duration of symptoms ≤28 days. A risk stratification approach based on the results of the multivariate analysis demonstrated that absence of signs and/or symptoms of congestive heart failure in younger (<50 years) patients with longer (>28 days) duration of disease appear to have an excellent prognosis with 100% survival and no events during FU (Figure 1). In contrast, presence of signs and/or symptoms of heart failure in older (≥50 years) patients with short duration (≤28 days) of the disease, results in a primary end-point occurrence of 35.9% during FU. Conclusions:For patients with biopsy-proven inflammatoric cardiomyopathy, symptoms of heart failure, short duration of disease, and older age, but not immunohistology or viral genome detection, were related to poor outcome.

A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy

“…The following supporting information can be downloaded at: , Supplementary Materials S1: Search keys utilized in database searches; Tables S1 and S2: A complete list of excluded studies with exclusion reasons; Table S3: All data included in studies; Table S4: Descriptions of reasons for exclusion of assessed miRNA. The references of papers cited in the Supplementary Materials are also cited here for the sake of completedness [ 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 ].…”